Share price · GPCR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GPCR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 29 Sep 2026-6.8%
Nothing announced by GPCR that day or the session before.
- 16 Sep 2026-8.9%
Nothing announced by GPCR that day or the session before.
- 8 Sep 2026-14.7%
- 9 Jun 2026+9.2%
Nothing announced by GPCR that day or the session before.
- 17 Apr 2026-5.1%
Nothing announced by GPCR that day or the session before.
- 8 Dec 2025+102.5%
- 18 Nov 2025-7.9%
Nothing announced by GPCR that day or the session before.
Share of unusual movement by asset
For each asset, the share of GPCR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
aleniglipronevents and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 57% |
| Other company news (earnings, financing, releases naming no asset) | — | 4% |
| Sessions with no dated event | — | 39% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GLP-1 receptorSmall molecule | ObesityType 2 Diabetes |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $135M | $222M+ $1.0B short-term inv. | $145M-$102M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $100M | $273M+ $1.1B short-term inv. | $106M-$120M operating cash flow | report ↗ |
| 2026-Q1 | — | $67M | $316M+ $1.1B short-term inv. | $76M$15M operating cash flow | report ↗ |
| 2025-Q3 | — | $59M | $103M+ $696M short-term inv. | $66M-$51M operating cash flow | report ↗ |
| 2025-Q2 | — | $55M | $147M+ $639M short-term inv. | $62M-$55M operating cash flow | report ↗ |
| 2025-Q1 | — | $43M | $152M+ $685M short-term inv. | $47M-$52M operating cash flow | report ↗ |
| 2024-Q3 | — | $33M | $172M+ $743M short-term inv. | $34M-$20M operating cash flow | report ↗ |
| 2024-Q2 | — | $22M | $382M+ $545M short-term inv. | $26M-$26M operating cash flow | report ↗ |
| 2024-Q1 | — | $21M | $98M+ $339M short-term inv. | $26M-$34M operating cash flow | report ↗ |
| 2023-Q3 | — | $18M | $51M+ $155M short-term inv. | $24M-$21M operating cash flow | report ↗ |
| 2023-Q2 | — | $19M | $41M+ $184M short-term inv. | $23M-$17M operating cash flow | report ↗ |
| 2023-Q1 | — | $13M | $126M+ $114M short-term inv. | $18M-$20M operating cash flow | report ↗ |
| 2022-Q3 | — | $9.2M | $28M | $12M-$10M operating cash flow | report ↗ |
| 2022-Q2 | — | $10M | $55M | $14M-$10M operating cash flow | report ↗ |
| 2022-Q1 | — | $8.5M | $51M | $13M-$14M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $225M | $800M+ $647M short-term inv. | $35M-$222M operating cash flow | report ↗ |
For full-year 2025, Structure Therapeutics did not disclose revenue. R&D expense was $225.26M, up 107.0% YoY from $108.81M. Cash and cash equivalents were $799.62M, while cash, cash equivalents and short-term investments totaled $1.4B at year-end. The company reported a full-year net loss of $141.2M, compared with $122.5M in 2024, and fourth-quarter net income of $33.0M.
The company expects its current cash to fund operations through the end of 2028. Positive aleniglipron Phase 2 ACCESS data showed up to 15.3% placebo-adjusted weight loss at 36 weeks; ACCESS II 44-week topline data are expected in Q1 2026, with Phase 3 initiation expected in 2H 2026. Initial Phase 1 data for ACCG-2671 and Phase 1 initiation of ACCG-3535 are expected in 2H 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $109M | $170M+ $714M short-term inv. | $31M-$117M operating cash flow | report ↗ |
| 2023-FY | — | $70M | $130M+ $338M short-term inv. | $22M-$79M operating cash flow | report ↗ |
| 2022-FY | — | $36M | $26M+ $65M short-term inv. | $13M-$46M operating cash flow | report ↗ |
| 2021-FY | — | — | $105M | — | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-21 | Coll Crespo Blas · CHIEF MEDICAL OFFICER | Conversion | 12,024 | — | — | Form 4 |
| 2026-09-21 | Coll Crespo Blas · CHIEF MEDICAL OFFICER | Conversion (derivative) | 4,008 | — | — | Form 4 |
| 2026-09-21 | Coll Crespo Blas · CHIEF MEDICAL OFFICER | Open-market sale (derivative) | 4,008 | $36.15 | $145K | Form 4 |
| 2026-09-18 | Coll Crespo Blas · CHIEF MEDICAL OFFICER | Tax withholding | 10,626 | $11.67 | $124K | Form 4 |
| 2026-09-01 | Lin Xichen · CHIEF SCIENTIFIC OFFICER | Option exercise | 17,817 | $0.34 | $6K | Form 4 |
| 2026-09-01 | Lin Xichen · CHIEF SCIENTIFIC OFFICER | Conversion | 17,817 | — | — | Form 4 |
| 2026-09-01 | Lin Xichen · CHIEF SCIENTIFIC OFFICER | Option exercise (derivative) | 17,817 | — | — | Form 4 |
| 2026-09-01 | Lin Xichen · CHIEF SCIENTIFIC OFFICER | Conversion (derivative) | 5,939 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 193 reporting institutions held 66.9M shares ($3.1B, 31.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 8,403,449 | $405.0M |
| 2 | WELLINGTON MANAGEMENT GROUP LLP | 7,260,287 | $349.9M |
| 3 | Avoro Capital Advisors LLC | 6,555,555 | $316.0M |
| 4 | JANUS HENDERSON GROUP PLC | 5,354,981 | $258.3M |
| 5 | Deep Track Capital, LP | 4,279,848 | $206.3M |
| 6 | BVF INC/IL | 3,459,358 | $166.7M |
| 7 | MORGAN STANLEY | 2,305,457 | $111.1M |
| 8 | PRINCIPAL FINANCIAL GROUP INC | 1,753,764 | $84.5M |
| 9 | Driehaus Capital Management LLC | 1,577,356 | $76.0M |
| 10 | ORBIMED ADVISORS LLC | 1,475,403 | $71.1M |
| 11 | AMERICAN CENTURY COMPANIES INC | 1,438,031 | $69.3M |
| 12 | BAKER BROS. ADVISORS LP | 1,432,529 | $69.0M |
| 13 | Siren, L.L.C. | 1,328,698 | $64.0M |
| 14 | Casdin Capital, LLC | 1,175,000 | $56.6M |
| 15 | CAPITOLIS LIQUID GLOBAL MARKETS LLC | 1,151,300 | $55.5M |